A stem cell journey in ophthalmology: From the bench to the clinic
Ingrid W. Caras, Lila R. Collins, Abla A. Creasey
Stem Cells Translational Medicine · 2021
doi:10.1002/sctm.21-0239 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract Debilitating diseases of the eye represent a large unmet medical need potentially addressable with stem cell‐based approaches. Over the past decade, the California Institute for Regenerative Medicine (CIRM) has funded and supported the translation, from early research concepts to human trials, of therapeutic stem cell approaches for dry age‐related macular degeneration, retinitis pigmentosa, and limbal stem cell deficiency. This article chronicles CIRM's journey in the ophthalmology field and discusses some key challenges and questions that were addressed along the way as well as questions that remain.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.